In-stent restenosis of superficial femoral artery: use all arrows in the quiver

Giuseppe Vadàlì1, Fabrizio Ceresa2, Francesco Costa3, Antonio Bottari3, Giuseppe Roscitano4, Francesco Patanè2 and Antonio Micari3,4,*

1Cardiovascular Department, University Hospital “Policlinico P. Giaccone”, Palermo, Italy
2Division of Cardiac Surgery, Department of Cardio-Thoraco-Vascular Surgery, Papardo Hospital, Messina, Italy
3Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy
4Department of General Surgery and Medical Specialties, University of Catania, Catania, Italy
*Correspondence address. Interventional Cardiology Department, Policlinic G. Martino, University of Messina, Via C. Valeria 1, Messina 98100, Italy.
E-mail: micarantonio@gmail.com

Abstract

In-stent restenosis (ISR) is a common superficial femoral artery (SFA) stenting complication, occurring in more than one third of patients within 2–3 years after the index procedure. Moreover, there is no standard treatment for ISR, and although many options are available, there is still limited data regarding its optimal management. We report a paradigmatic case report of a patient complaining of symptomatic peripheral arterial disease, underwent multiple endovascular revascularizations for recurrent femoro-popliteal ISR. A step-by-step approach was followed. At the time of the first presentation, the ISR was treated by drug-eluting balloon (DEB) angioplasty. The repeated ISR was treated by laser debulking, achieving a good angiographic result. Finally, after the third repeated restenosis, a combined approach with laser debulking and DEB angioplasty guaranteed a good acute angiographic result. Long-term duplex-scan follow-up demonstrated the good patency of the femoro-popliteal target lesion.

A 53-year-old man treated with percutaneous transluminal angioplasty (PTA) and bare-metal stent in the left superficial femoral artery (SFA), popliteal artery and tibioperoneal trunk 1 year earlier (Fig. 1A and B), presented with recurrent symptoms of Rutherford stage 3 claudication. He was an active heavy smoker since he was 18 years old and hypercholesterolemic on treatment with statins. No other cardiovascular risk factors or diseases were reported in the past medical history. He was scheduled to repeat the lower limb revascularization. Selective angiography revealed severe in-stent restenosis (ISR) (i.e. Tosaka class 2; Fig 1C), which was treated with PTA and paclitaxel drug-eluting balloon (DEB) (Impact Pacific 4.0/150 and 5.0/80, Medtronic Vascular, Santa Clara, CA) with a satisfactory result (Fig. 1D). After 18 months, the patient suffered rapidly evolving recurrent pain at rest. Duplex scan and angiography revealed recurrent ISR, with a focal pattern (Tosaka class 1; Fig. 2A and B). Re-intervention was carried out with lesion debulking with excimer laser atherectomy (TurboTandem, Spectranetics, Colorado Springs, CO) followed by re-PTA with paclitaxel DEB (Impact Admiral 4.0/120 and 5.0/120, Medtronic Vascular, Santa Clara, CA), with good immediate result (Fig. 3A and B). The patient remained free of symptoms thereafter and 24-month duplex scan revealed stent patency without signs of ISR (Fig. 3C).

DISCUSSION

ISR is a frequent complication of SFA stenting, occurring in ~40% of patients within 2–3 years after device implantation. Currently, there is no standard treatment for ISR, and although many options are available, there is still limited data regarding its optimal management. In this paradigmatic case, we have shown that re-intervention after SFA is common, and different approaches have been needed to achieve longer-term results. Data from randomized controlled trials (RCT) and meta-analysis confidently show that PTA with DEB is superior to plain balloon angioplasty in terms of patency rate and target lesion revascularization, reducing the risk of re-intervention by 56% at 12 months [1]. Yet, results with different types of DEB have been inconsistent. Hence, given the heterogeneous clinical response to different DEB technologies, results from trials should be considered device-specific rather than class-specific [2, 3]. In our case, treatment with DEB provided good immediate results, but focal ISR was evident within 18 months. A mixed technique including both atherectomy and DEB angioplasty provided better results. At difference with de novo atherosclerosis, ISR is predominantly caused by neointimal hyperplasia, with excessive proliferation of smooth muscle cells and hydrated collagen matrix. Direct removal of this tissue with atherectomy and subsequent elution of antiproliferative drug through DEB could provide more durable results. To date, only one RCT compared DEB alone with atherectomy plus DEB, showing better stent patency at 12 months, with roughly halved ISR rates in the experimental arm [4]. These data are in line with our explanatory case, yet this was a single center, relatively small, study. In addition, results from this trial do not necessarily apply to all kinds of atherectomy devices. The optimal treatment for ISR is still unknown, and future studies testing DEB (and types thereof), atherectomy (and types thereof), covered stents or drug-
eluting stents should be rigorously conducted to provide novel insights in this field.

CONFLICT OF INTEREST

No conflicts of interest must be declared.

FUNDING

This is an own work. No funds must be declared.

ETHICAL APPROVAL

For the case report submission is not required an ethical approval of our Institution.

CONSENT

The patient provided the consent to undergo all the endovascular procedures and he provided the authorization for his case publication.

GUARANTOR

All the authors are nominated Guarantor of the manuscript.

REFERENCES

1. Tong Z, Guo L, Qi L, Cui S, Gao X, Li Y et al. Drug-coated balloon angioplasty and debulking for the treatment of femoropopliteal in-stent restenosis: a systematic review and meta-analysis. Biomed Res Int 2020;2020:3076346–14. https://doi.org/10.1155/2020/3076346.
2. Micari A, Cioppa A, Vadalà G, Stabile E, Castriota F, Pantaleo P et al. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results. EuroIntervention 2011;7:K77–82. https://doi.org/10.4244/EIJV7SKA14.
3. Scheinert D, Micari A, Brodmann M, Tepe G, Peeters P, Jaff MR et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv 2018;11:e005654. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005654.
4. Gandini R, Del Giudice C, Merolla S, Morosetti D, Pampana E, Simonetti G. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther 2013;20:805–14. https://doi.org/10.1583/13-4308MR.1.